A5019412832- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- BRCA gene mutations in cancer
- Global Cancer Incidence and Screening
- Estrogen and related hormone effects
- Cancer Risks and Factors
- Economic and Financial Impacts of Cancer
- Cancer Genomics and Diagnostics
- Women's cancer prevention and management
- Peptidase Inhibition and Analysis
- Colorectal Cancer Treatments and Studies
- Monoclonal and Polyclonal Antibodies Research
- Nutrition, Genetics, and Disease
- Cancer Immunotherapy and Biomarkers
- Breast Lesions and Carcinomas
- Health Systems, Economic Evaluations, Quality of Life
- Advances in Oncology and Radiotherapy
- Cancer Cells and Metastasis
- Chemotherapy-induced cardiotoxicity and mitigation
- Immunotherapy and Immune Responses
- Molecular Biology Techniques and Applications
- Genomics and Rare Diseases
- Lung Cancer Treatments and Mutations
Instituto Nacional do Câncer
2016-2025
D’Or Institute for Research and Education
2020-2025
Universidade Federal de Ciências da Saúde de Porto Alegre
2024
Fleury S.A. (Brazil)
2024
Eastern Cooperative Oncology Group
2023
Hospital do Câncer III
2018-2022
Roche (Switzerland)
2017-2021
MSD (Latvia)
2021
Novartis (Switzerland)
2021
Pfizer (United States)
2021
Pertuzumab increases the rate of pathological complete response in preoperative context and overall survival among patients with metastatic disease when it is added to trastuzumab chemotherapy for treatment human epidermal growth factor receptor 2 (HER2)–positive breast cancer. In this trial, we investigated whether pertuzumab, adjuvant chemotherapy, improves outcomes HER2-positive early
Purpose The third-generation nonsteroidal aromatase inhibitors (AIs) are increasingly used as adjuvant and first-line advanced therapy for postmenopausal, hormone receptor–positive (HR+) breast cancer. Because many patients subsequently experience progression or relapse, it is important to identify agents with efficacy after AI failure. Materials Methods Evaluation of Faslodex versus Exemestane Clinical Trial (EFECT) a randomized, double-blind, placebo controlled, multicenter phase III trial...
Purpose Lapatinib, a dual tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR/ErbB1) and human 2 (HER-2/ErbB2), is effective against HER-2–positive locally advanced or metastatic breast cancer (MBC). This phase III trial evaluated the efficacy lapatinib in HER-2–negative HER-2–uncharacterized MBC. Patients Methods Women with MBC were randomly assigned to first-line therapy paclitaxel 175 mg/m every 3 weeks plus 1,500 mg/d placebo. A preplanned retrospective evaluation HER-2...
The Pre-Operative "Arimidex" Compared to Tamoxifen (PROACT) study was a randomized, multicenter comparing anastrozole with tamoxifen as preoperative treatment of postmenopausal women large, operable (T2/3, N0-2, M0), or potentially (T4b, M0) breast cancer. effect endocrine therapy in patients scheduled for mastectomy inoperable tumors at baseline also investigated.Patients hormone receptor-positive cancer received (n = 228) 223) without chemotherapy 12 weeks before primary surgery.Objective...
APHINITY, at 45 months median follow-up, showed that pertuzumab added to adjuvant trastuzumab and chemotherapy significantly improved invasive disease-free survival (IDFS) (hazard ratio 0.81 [95% CI, 0.66 1.00], P = .045) for patients with early human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC), specifically those node-positive or hormone (HR)-negative disease. We now report the preplanned second interim overall (OS) descriptive updated IDFS analysis 74...
PURPOSE The global, phase 3, open-label, randomized TROPION-Breast01 study assessed the trophoblast cell surface antigen 2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) versus investigator's choice of chemotherapy (ICC) in hormone receptor–positive/human epidermal growth factor receptor 2–negative (HR+/HER2–) breast cancer. METHODS Adult patients with inoperable/metastatic HR+/HER2‒ cancer, who had disease progression on endocrine therapy, for whom therapy was...
Operable triple-negative breast cancers (TNBCs) have a higher risk of relapse than non-TNBCs with standard therapy. The GEICAM/2003-11_CIBOMA/2004-01 trial explored extended adjuvant capecitabine after completion chemotherapy in patients early TNBC.Eligible were those operable, node-positive-or node negative tumor 1 cm or greater-TNBC, prior anthracycline- and/or taxane-containing chemotherapy. After central confirmation TNBC status by immunohistochemistry, randomly assigned to either...
Breast cancer is the most common malignancy in women Brazil. Differences between patients with public versus private healthcare coverage about general characteristics, disease presentation, treatment of primary tumors, and clinical outcomes have not been fully investigated.A national, retrospective cohort 3,142 drawn from a representative sample Brazilian medical centers was selected. Clinical demographic data type were retrieved by chart review. Groups compared using χ(2) test. The log-rank...
In premenopausal patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer, the gonadotoxicity of trastuzumab and lapatinib remains largely uncertain, prognostic effect treatment-related amenorrhea (TRA) is unknown. Adjuvant Lapatinib and/or Trastuzumab Treatment Optimization (BIG 2-06) phase III trial, HER2-positive cancer were randomized (1:1:1:1) to receive one year trastuzumab, lapatinib, their sequence, or combination. As per study protocol, menopausal...
The detection of germline mutations in BRCA1 and BRCA2 is essential to the formulation clinical management strategies, Brazil, there limited access these services, mainly due costs/availability genetic testing. Aiming at identification recurrent that could be included a low-cost mutation panel, used as first screening approach, we compiled testing reports 649 probands with pathogenic/likely pathogenic variants referred 28 public private health care centers distributed across 11 Brazilian...
A key determinant of breast cancer outcome is the degree to which newly diagnosed cancers are treated correctly in a timely fashion. Available resources must be applied rational manner optimize population-based outcomes. multidisciplinary international panel experts addressed implementation treatment guidelines and developed process checklists for surgery, radiation treatment, systemic therapy. The needed stage I, II, locally advanced, metastatic were outlined, metrics developed. ability...
Breast cancer (BC) in young women is uncommon and tends to present with more aggressive characteristics. To better understand characterize this scenario Brazil through real-world data, we performed a subanalysis of AMAZONA III study (ClinicalTrials.gov identifier: NCT02663973).The (GBECAM 0115) prospective registry that included 2,950 newly diagnosed invasive BC from January 2016 until March 2018 at 22 sites. Valid data were obtained 2,888 patients regarding age diagnosis complete baseline...
Treating breast cancer under the constraints of significantly limited health care resources poses unique challenges that are not well addressed by existing guidelines. We present evidence-based guidelines for systematically prioritizing therapies across entire spectrum resource levels. After consideration factors affecting value a given therapy (contribution to overall survival, disease-free quality life, and cost), we assigned each one four incremental levels--basic, limited, enhanced, or...
Neoadjuvant pembrolizumab plus chemotherapy (P + CT) has emerged as a standard of care for stage II-III triple-negative breast cancer (TNBC). However, the best anthracycline-cyclophosphamide (AC) schedule remains to be determined. While KEYNOTE-522 regimen employs AC every 3 weeks (q3w AC), previous studies have shown overall survival benefits dose-dense regimens early-stage cancer. The Neo-Real study (GBECAM-0123) is real-world data effort evaluating patients with TNBC treated neoadjuvant P...